ATE353659T1 - Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung - Google Patents

Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung

Info

Publication number
ATE353659T1
ATE353659T1 AT02717908T AT02717908T ATE353659T1 AT E353659 T1 ATE353659 T1 AT E353659T1 AT 02717908 T AT02717908 T AT 02717908T AT 02717908 T AT02717908 T AT 02717908T AT E353659 T1 ATE353659 T1 AT E353659T1
Authority
AT
Austria
Prior art keywords
methods
treating
inflammatory component
brain disease
blood
Prior art date
Application number
AT02717908T
Other languages
English (en)
Inventor
Anthony E Bolton
Arkady Mandel
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of ATE353659T1 publication Critical patent/ATE353659T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02717908T 2001-04-06 2002-04-08 Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung ATE353659T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28212001P 2001-04-06 2001-04-06

Publications (1)

Publication Number Publication Date
ATE353659T1 true ATE353659T1 (de) 2007-03-15

Family

ID=23080183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717908T ATE353659T1 (de) 2001-04-06 2002-04-08 Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung

Country Status (9)

Country Link
US (1) US7122208B2 (de)
EP (1) EP1379260B1 (de)
JP (1) JP2005508847A (de)
AT (1) ATE353659T1 (de)
AU (1) AU2002249034B2 (de)
CA (1) CA2442313A1 (de)
DE (1) DE60218146T9 (de)
ES (1) ES2282405T3 (de)
WO (1) WO2002080945A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
WO2004010852A2 (en) 2002-07-31 2004-02-05 Kropp Bradley P Tissue compositions and methods for producing same
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
WO2008136958A1 (en) * 2007-04-30 2008-11-13 Opthera, Inc. Uva1-led phototherapy device and method
EP2442819A4 (de) * 2009-06-19 2013-01-02 Acquisci Inc Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon
CN102802643A (zh) * 2009-06-19 2012-11-28 阿奎赛公司 利用臭氧治疗炎性病症、心血管疾病和急性缺血性脑中风
WO2013151682A1 (en) 2012-04-06 2013-10-10 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
EP2968825A4 (de) * 2013-03-15 2016-09-07 Childrens Medical Center Gasgefüllte stabilisierte teilchen und verfahren zur verwendung
US11147890B2 (en) 2017-02-28 2021-10-19 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
US11717698B1 (en) 2020-04-23 2023-08-08 Hugh McGrath, Jr. Therapy, treatment, and process for photodynamic inactivation of COVID-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3989949B2 (ja) 1992-02-07 2007-10-10 バソジェン アイルランド リミテッド 血中の酸化窒素濃度を増加させる方法
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
ATE246929T1 (de) 1995-05-05 2003-08-15 Vasogen Ireland Ltd Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
CA2206180A1 (en) 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
JP2002534473A (ja) 1999-01-12 2002-10-15 パヴェル ハメット， 細胞死に対する予備条件付け

Also Published As

Publication number Publication date
ES2282405T3 (es) 2007-10-16
US20020155098A1 (en) 2002-10-24
JP2005508847A (ja) 2005-04-07
EP1379260A2 (de) 2004-01-14
DE60218146T9 (de) 2008-02-21
DE60218146T2 (de) 2007-11-22
WO2002080945A2 (en) 2002-10-17
EP1379260B1 (de) 2007-02-14
AU2002249034B2 (en) 2007-08-02
US7122208B2 (en) 2006-10-17
WO2002080945A3 (en) 2003-06-26
CA2442313A1 (en) 2002-10-17
DE60218146D1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
ATE353659T1 (de) Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60005952D1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
DE60138371D1 (de) PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties